Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the 10Q:
The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI).
While the Company’s HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS, they may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current antiretroviral therapy for several significant reasons:
(1) the therapy will be non-toxic (without damage to the kidneys and liver) and will not cause bone densitydeterioration (osteopenia and osteoporosis) – as does antiretroviral treatments, (2) will not require lifetime treatment and (3) will be far less expensive.
It doesn't say ITV-1 is going to cure Covid.
Misinformation now that is funny here is the quote - "that will shake the world with our fabulous treatments/cures for HIV-AIDS, COVID, & other viral infectious diseases!"
Those treatments/cures ENZC has been working on for HIV-AIDS, COVID, & other viral infectious diseases are mAbs that will be going into clinical trials sooner than later.
Dr. Joseph Cotropia will assume the Chief Scientific Officer position of Biogenysis. Dr. Cotropia said, "I am encouraged to see a roadmap and strategies in place to fulfill my life's work. We were few when we started, and it is encouraging to now have many professionals and partnering companies that believe in our science and therapies. Our AI platform and the collaboration we have with Samsung Biologics will accelerate our progress. Since the steps from early discovery to IND studies are identical, we can move ahead rapidly with production of multiple Monoclonal Antibodies."
https://www.accesswire.com/751584/Enzolytics-Inc-Continues-Progress-with-Business-Combination-Biogenysis-Announces-Team-and-Plans-for-Success
There you go again with your MISINFORMATION.
Where in Bonnie's post does it say ITV-1 cures Covid?
The only misinformation is coming from you.
Who said ?: ITV-1 was approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
Who said?: ENZC has done any FDA approved clinical trials for ITV-1.
You said:
Life Science Review Magazine
https://www.lifesciencesreview.com/about-us/
The publication, which reaches a combined digital and print subscriber base of over 124,000, targets senior and executive-level life sciences professionals to provide them with unique insights into the ever-evolving industry.
What is the impact factor of Life Sciences review?
Life Sciences is a weekly peer-reviewed scientific journal covering research on the molecular, cellular, and physiological mechanisms of pharmacotherapy.
Top 10 Life science Technology Magazines
4. Life Sciences Review
Life Sciences Review aims to provide real-life knowledge, best management practices, and advances in the science, technology, solutions, and service offerings by vendors to assist organizations to thrive in challenging times. They aim to bring buyers’ perspectives, needs, and challenges in managing their organizations and working with solutions and services providers. Their goal is to provide a vendor-neutral platform where leaders in the Life Science Industry can learn from challenges facing their peers and approaches being taken by different organizations to make their organizations successful.
https://georgekaren654.medium.com/top-10-life-science-technology-magazines-b3019967e82e
ENZC is a high risk high reward OTC stock.
We are now in a high RISK area.
We were in a high REWARD area last week.
The long term forecast for ENZC is high REWARD with various risks along the way.
While the ITV-1 immunotherapy treatment in Africa is a step in the right direction, IMHO ENZC has BIGGER plans to be revealed sooner than later that led to the SPAC deal.
ENZC has been working tirelessly in the laboratory developing mAbs that is going to change the pharmaceutical industry like never before.
ENZC is on more solid footing today than they were 3 years ago.
We are guaranteed nothing however the sky is the limit with all the potential ENZC has.
Will ENZC DELIVER?
Regeneron anticipate initiating clinical trial in mid-2023 on Next-gen COVID antibody.
https://investor.regeneron.com/static-files/dbe7aad3-8aff-483f-9366-fa1678d7b738
Slide 20
We appreciate your research.
Now tell us something we don't know that is the truth, the whole truth and nothing but the truth.
My research is stellar.
You said in your post:
I-Glow
Member Level
Re: DRHUMI post# 176349
Friday, May 12, 2023 12:38:16 PM
Post#
176352
of 176373
The OTC is for trading not investing!
Play the price action and always take profits.
ENZC is such an obvious scam and they are going to have big problems with the SEC about the pumping press release for the fake deal for $250M with SAGA.
The SAGA CEO has resigned.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=1718976
There is a BIG difference between a CEO and a CFO.
Have you researched the European database yet.
You are right the SAGA CEO resigned.
The only problem is you have the wrong company:
Saga Pure: Bjørn Simonsen to step down as CEO
THU, DEC 22, 2022 19:30 CETReport this content
(Oslo, 22 December 2022) Chief Executive Officer (CEO) Bjørn Simonsen of Saga Pure ASA (Saga Pure, OSE: SAGA) will step down effective 15 January 2023. The Board of Directors has initiated the succession process.
As usual you are WRONG again.
Have you searched the European database YET!
Giddy up ENZC Giddy up
Why would clinical trials being conducted in Europe be in a US database.
Look in the European database and let us know if you find anything.
Where do you think the ITV-1 therapeutic that is now in Africa treating patients was developed?
Where do you think the monoclonal antibodies for infectious diseases was developed?
Enzolytics, Inc.Texas A&M Institute for Preclinical StudiesEnzolytics, Inc.800 Raymond Stotzer ParkwayCollege Station, Texas 77843-4478
IMHO we will see MASSIVE mAbs update sooner than later.
ENZC has been very busy in the laboratory these past few years.
IPF Immune is in the marketplace
ITV-1 therapeutic is treating patients in Africa
Anti-HIV Monoclonal Antibody Therapy may be very close to an IND filing based on past ENZC press releases:
(Newsfile Corp. - May 16, 2022) https://www.newsfilecorp.com/release/124101/Enzolytics-Inc.-Discusses-the-Significance-and-Revenue-Potential-of-Its-Therapeutic-Platforms-with-The-Stock-Day-Podcast:
HIV THERAPEUTICS
Addressing the HIV pandemic, the Company has two expectedly complementary therapeutics directed to the effective treatment of HIV. One therapeutic, ITV-1, a patented antiviral peptide that has been clinically tested, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. This therapeutic has been shown to strengthen the immune system and has been tested in HIV patients in clinical trials with significant beneficial results. [https://enzolytics.com/proprietary-therapeutics/]. Currently, the Company is advancing this anti-HIV therapeutic for approval under the European Medicines Agency (EMA) for use in European Union countries.
The Company also is focused on deploying this tested therapeutic in African countries, where the HIV pandemic is severe. Upon completion of final Toxicity Studies of ITV-1, the Company plans to be able to make ITV-1 available in the countries in Africa, including Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa. The Company sees this as significant for individuals in Africa recognizing that out of the 38.4 Million HIV-positive people worldwide, 69% live in sub-Saharan Africa. There are roughly 23.8 Million infected persons in all of Africa. 40% of those infected with HIV in Africa do not have any access to any treatment for the virus. In addition, 91% of the world's HIV-positive children live in Africa.
The second therapeutic for treating HIV, the Company's anti-HIV monoclonal antibodies, are also in development. The Company's primary anti-HIV antibody has been produced from the parent antibody in the recombinant form (a form necessary for patient treatment) by Samsung Biologics. Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV Monoclonal Antibody Therapy for the treatment of HIV. The Company notes that this anti-HIV mAb targets an immutable site on the HIV virus that has existed unchanged over 30 years of analysis of the virus. This means that the target will not mutate rendering the antibody ineffective.
COLLEGE STATION, TX / ACCESSWIRE / December 1, 2022 https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/12132162/enzolytics-recognizes-world-aids-day-and-highlights-the-companys-focus-on-producing-effective-therapies-for-treating-hiv/
HIV THERAPEUTICS
Addressing the HIV pandemic, the Company has two expectedly complementary therapeutics directed to the effective treatment of HIV. One therapeutic, ITV-1, a patented antiviral peptide that has been clinically tested, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. This therapeutic has been shown to strengthen the immune system and has been tested in HIV patients in clinical trials with significant beneficial results. [https://enzolytics.com/proprietary-therapeutics/]. Currently, the Company is advancing this anti-HIV therapeutic for approval under the European Medicines Agency (EMA) for use in European Union countries.
The Company also is focused on deploying this tested therapeutic in African countries, where the HIV pandemic is severe. Upon completion of final Toxicity Studies of ITV-1, the Company plans to be able to make ITV-1 available in the countries in Africa, including Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa. The Company sees this as significant for individuals in Africa recognizing that out of the 38.4 Million HIV-positive people worldwide, 69% live in sub-Saharan Africa. There are roughly 23.8 Million infected persons in all of Africa. 40% of those infected with HIV in Africa do not have any access to any treatment for the virus. In addition, 91% of the world's HIV-positive children live in Africa.
The second therapeutic for treating HIV, the Company's anti-HIV monoclonal antibodies, are also in development. The Company's primary anti-HIV antibody has been produced from the parent antibody in the recombinant form (a form necessary for patient treatment) by Samsung Biologics. Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for Anti-HIV Monoclonal Antibody Therapy for the treatment of HIV. The Company notes that this anti-HIV mAb targets an immutable site on the HIV virus that has existed unchanged over 30 years of analysis of the virus. This means that the target will not mutate rendering the antibody ineffective.
COLLEGE STATION, TX / ACCESSWIRE / December 13, 2022 https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/12457227/enzolytics-inc-announces-us-distribution-of-ipf-immunetm-and-progress-in-each-of-its-therapeutic-platforms/
Enzolytics' methodology for producing monoclonal antibodies is unique and innovative, unlike other biotech companies. The Company's antibodies are produced from human "immune-B cells" obtained from convalescent individuals who have recovered from the target virus. The Company's monoclonal antibodies are not "humanized" but are fully human monoclonal antibodies where the original antibody affinity and specificity are maintained.
The methodology starts with human "immune cells" obtained from convalescent individuals who have recovered from the virus. From these human B cells, the Company then produces antibodies that target conserved immutable sites (neutralizable epitopes) on the virus' surface envelope proteins that will be ever-present, rendering the virus neutralizable even through mutation, thus voiding "virus escape". These antibodies also retain the original natural antibody's affinity and specificity and have a very low risk of immunogenicity when used as a therapeutic.
Once produced, the monoclonal antibodies are tested for binding and neutralizing activity. These characteristics are confirmed by the Company's partnering laboratories, Genscript Labs and the University of Strasbourg, France. After the final confirmation of antibody activity, the Company's CDMO partner Samsung Biologics will produce the recombinant antibodies in their proprietary, FDA-approved stable CHO cell line suitable for Clinical Application. https://www.bloomberg.com/press-releases/2021-10-07/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2.
Enzolytics is developing Class switched IgA1/2 Clone 3 Antibodies. This therapy will expectedly provide a protective immunological defense against an initial exposure to HIV at mucosal surfaces, such as in the passage of the virus from mother to child through maternal breastfeeding. HIV mucosal infection plays a critical role in virus transmission and AIDS pathogenesis, affecting mucosal surfaces of the gastrointestinal tract early on by depleting CD4+ T helper cells independently of the virus transmission route. Although current antiretroviral therapy is intended to control HIV infection in most patients, it cannot eradicate the virus from the human host. Therefore, the development and use of HIV microbicides (i.e., topical pre-exposure prophylaxis) have become a most promising approach to preventing HIV transmission. Thus, the development of Class switched Clone 3 IgA1/IgA2 is highly significant. In addition to the anti-HIV monoclonal antibody already produced and tested, Enzolytics is producing monoclonal antibodies targeting the additional seven conserved targets identified by the A.I. platform.
The Company COO Dr. Gaurav Chandra noted, "While the Company's focus is on producing monoclonal antibodies for treating human viruses, the Company is now applying its technology in the production of monoclonal antibodies against animal viruses, including Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV). The Company has analyzed, using Artificial Intelligence, epitopes of these viruses and has identified conserved sites against which targeting monoclonal antibodies are being developed. The Company has also analyzed epitopes of the Equine Infectious Anemia Virus, Koala Retrovirus, Elephant Endotheliotropic Herpes Virus (EEHV), Avian Flu Swine Flu, and others. This analysis has revealed the conserved immutable sites on these viruses against which monoclonal antibody production is planned.
The production of these monoclonal antibodies begins in the Company's lab located at the Texas A&M University Institute for Preclinical Studies [https://tips.tamu.edu/]. Using the Company's proprietary methodology for producing fully human monoclonal antibodies which target conserved, immutable sites on the viruses, multiple monoclonal antibodies are being produced."
Producing antibodies for the treatment of Feline Leukemia Virus and Feline Immunodeficiency Virus is significant because these viruses are the most common infectious diseases in cats. There are more than 150 million cats in the U.S. and over 25% of households in America own cats. These Feline viruses a significant percentage of the cat population in the United States and around the world. Production of monoclonal antibodies targeting these viruses will be more direct and the time to market will be significantly less than is the case required for monoclonal antibodies developed for the treatment of individuals. The Company has initiated discussions with animal health providers who express an interest in this technology and its end product.
The Company's primary anti-HIV monoclonal antibody (Clone 3) has been produced and successfully tested in vitro against multiple virus strains, showing complete efficacy. The recombinant form of the parent antibody (necessary for patient therapy) has been successfully produced for the Company by Samsung Biologics. This recombinant Antibody is undergoing efficacy testing and has shown significant activity even against drug-resistant HIV strains. Studies have confirmed the dual tropic activity of the HIV monoclonal antibody - Clone 3.
The Company CSO Dr. Joseph Cotropia said, "For HIV to be infectious, there is a requirement of specific binding between the virus envelope protein and the human CD4 cell at two receptor sites on the CD4 cells, namely: (1) binding to CD4 receptor initially (on gp120), and (2) binding to the chemokine co-receptors CXCR4 and/or CCR5 (on gp41). The Clone 3 Antibody interrupts the binding of the virus transmembrane gp41 to the human CD4 cells via blocking of binding to the 2nd co-receptor-to both the CCR5 and the CXCR4 receptors-on the CD4 cell surface. Because Clone 3 is dual-tropic, it consequently prevents HIV infection by abrogating the essential infectivity process which requires the fusion between the viral membrane and the human CD4 cell membrane."
In view of the test results completed on the Company's Clone 3 Monoclonal Antibody and ITV-1 activity, plans are in place to assess combination therapy using these 2 therapeutics to treat HIV.
COLLEGE STATION, TX / ACCESSWIRE / February 8, 2023 https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/14009682/enzolytics-announces-preliminary-results-of-glp-toxicology-study-for-its-anti-hiv-therapeutic-itv-1-and-production-of-itv-1-for-initiation-of-registration-in-africa/
The Company COO, Dr. Gaurav Chandra, said, "The Company has made significant progress on its multiple therapeutic platforms. These platforms include the Company's ongoing development of multiple Monoclonal Antibodies for the treatment of various infectious diseases, an AI platform that makes possible rapid production of effective multiple Monoclonal Antibodies, including those targeting both human and animal viruses, and an effective nutritional supplement, IPF Immune™, that is currently on the market. With several therapeutic platforms providing significant value to the Company and its shareholders, we are confident in our future. The Company's strengths are its multiple technologies that will individually provide effective therapies and treatments for patients and consumers."
COLLEGE STATION, TX / ACCESSWIRE / April 17, 2023 /https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/16033356/enzolytics-inc-announces-execution-of-non-binding-term-sheet-with-the-special-purpose-acquisition-company-sagaliam-acquisition-corp-and-updates-the-progress-on-the-african-project/
The CEO of BGEN, Dr. Gaurav Chandra, emphasized the progress being made by the Company using its Artificial Intelligence (AI) platform. "We continue to utilize our disruptive AI platform to identify conserved immutable epitopes on viruses and then produce species-specific monoclonal antibodies targeting those sites. We are advancing in production of multiple monoclonal antibodies against HIV, SARS-CoV-2, and the Feline Leukemia virus. Our AI platform drives the Company's drug discovery and development and executes our strategy to produce multiple therapeutics protected by International Patents. We take pride in strengthening our IP portfolio and protecting the anti-virus therapeutics, their production method, use in diagnostics and prognostics. Our application of Artificial Intelligence to drug formulation and creation is a move ahead of big pharma's monoclonal antibody discovery and development. We recognize that large pharmaceutical companies are now focused more than ever on the significant advantage provided by AI in creating highly successful therapeutics. We continue to engage with large pharma and discuss potential partnerships involving our AI platform."
Enzolytics CEO Charles Cotropia stated, "Enzolytics is focused on accelerating the growth of our clinical products, technology platforms and multiple programs now in progress. This agreement with Sagaliam will allow us to accelerate progress in each of these areas."
COLLEGE STATION, TX / ACCESSWIRE / April 27, 2023 / https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/16359745/enzolytics-inc-continues-progress-with-business-combination-biogenysis-announces-team-and-plans-for-success/
Dr. Joseph Cotropia will assume the Chief Scientific Officer position of Biogenysis. Dr. Cotropia said, "I am encouraged to see a roadmap and strategies in place to fulfill my life's work. We were few when we started, and it is encouraging to now have many professionals and partnering companies that believe in our science and therapies. Our AI platform and the collaboration we have with Samsung Biologics will accelerate our progress. Since the steps from early discovery to IND studies are identical, we can move ahead rapidly with production of multiple Monoclonal Antibodies."
Dr. Suraj Saggar will be an Advisory Board Member of Biogenysis. Dr. Saggar said, "There is tremendous progress in developing our Monoclonal Antibodies for multiple infectious diseases. Besides IgG Monoclonal Antibodies, the IgA Monoclonal Antibodies for COVID-19 have disruptive potential. In addition, we recognize the role of IgA antibodies in the immune function of mucous membranes and are working on harnessing their potential for powerful, efficient Immunotherapeutics. These can be offered as an intranasal spray which can be easily applied to achieve long-term protection."
Charles Cotropia, CEO of Enzolytics, stated, "At Biogenysis, we have a pipeline of Monoclonal Antibodies. In addition, we are creating a strong IP portfolio for multiple infectious diseases covering diagnostics, therapeutics, and vaccines for these viruses. Strategically, we are focused on meeting milestones and licensing each of these assets. The SPAC agreement allows us to move forward with multiple Monoclonal Antibodies simultaneously, bringing significant value to our shareholders."
Not yet.
I'm 63 pretty healthy although I have to deal with my prostate.
My father had prostate cancer and lived with it for 25 years.
He died at 92 on his 63rd wedding anniversary.
My oldest brother was taken out by it at 67.
My second oldest brother and younger brother has it under control.
My PSA reading popped up this year so I'm doing a biopsy and take it from there depending on the results.
This Podcast is from a year ago.
I wonder how far ENZC has progressed with the four monoclonal antibodies for infectious diseases that were in clinical development when this message was released.
Enzolytics, Inc. Discusses the Significance and Revenue Potential of Its Therapeutic Platforms with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - May 16, 2022) - The Stock Day Podcast welcomed Enzolytics, Inc. (ENZC) ("the Company"), a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. Director and COO of the Company, Dr. Gaurav Chandra, joined Stock Day host Everett Jolly.
"Could you tell us about IPF Immune™ and the success you're hoping it will bring to the Company?", asked Jolly to begin the interview. "IPF Immune™ is a science-backed immune modulator that helps strengthen the body's defenses against viruses or other pathogens," explained Dr. Chandra, adding that the product stimulates the body's natural immune system, without producing any side effects. "It works as an immune booster that increases the ability of the immune system to fight infections, and in addition it enhances recovery and reduces the recovery period after an illness."
"While we have already launched IPF Immune™ in the United States, we are also launching the product in Europe and Canada in the next three months," continued Dr. Chandra, noting the revenue potential of this product.
Dr. Chandra then elaborated on the significance of IPF Immune™, citing positive results during testing against the CoronaVirus (SARS-CoV-2) strain 229e. "It actually showed comparable efficacy, but with 24 times lower toxicity than the widely used antiviral, Tamiflu," said Dr. Chandra, noting the product's additional applications. Additionally, he said that our preliminary studies with IPF-Immune have demonstrated significant in-vitro neutralization activity against Adenovirus. "In the next couple of weeks, we will be sharing efficacy data with our shareholders."
"Do you have any revenue projections for IPF Immune™ going forward?", asked Jolly. "We do have revenue projections, and they are extremely healthy projections," shared Dr. Chandra. "The immune modulator market is large and growing," he added. "It's a $50 billion nutritional supplement market, so we expect significant revenues in the upcoming year."
Jolly commented on the Company's numerous product platforms, including their patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), as well as their monoclonal antibody program, and asked what makes the Company so special. "We have identified the conserved immutable targets in about 20 viruses, and then we went a bit further," said Dr. Chandra. "We built AI-based three-dimensional models of these immutable targets and established linearity, neutralization by antibodies or accessibility by antibodies, before moving forward to develop monoclonal antibodies that target these specific sequences."
"We actually did the same thing for HIV viruses," he continued. "We identified 8 conserved immutable targets," said Dr. Chandra. "The virus can mutate many times, but since these are conserved it will remain unchanged," he explained. "The resulting monoclonal antibodies that we have created are universal, durable, broadly utilizing, and will remain unaffected by mutations or viruse escape."
Dr. Chandra then discussed the importance of AI-driven diagnostics. "We are discussing partnerships with diagnostic companies that have a track record of getting diagnostics tests through Regulatory approval and distributing these diagnostic tests for clinical use.," said Dr. Chandra. "As viruses mutate, the diagnostic test for them have to be modified to identify each mutant of the virus," he said. "But since the targets we have identified remain unchanged, if those target sites are used to diagnose the virus, then you have a test that is universally applicable even for mutants of the viruses."
Talking about AI-driven prognostics he said that there are documented studies showing better prognosis and clinical outcomes in patients with antibodies to the AI-identified conserved targets. Enzolytics is also discussing a potential partnership to develop a prognostic test that predicts immune response before receiving a vaccine or antiviral therapy.
"Since we have the capability of identifying conserved targets, we are actually working to be a part of consortiums that are looking to prevent the next global pandemic, and that is very exciting for us," shared Dr. Chandra. "The AI platform significantly cuts down the time for our drug discovery and development."
"Where is Enzolytics at with collaborations moving forward?", asked Jolly. "At Enzolytics, we build a product and put effort into R&D, and then we intend to partner with a larger entity, a large pharmaceutical company, that can take it through the clinical stages quickly," said Dr. Chandra. "We need to make sure our products reach patients as soon as possible."
"Have you considered where your valuation may end up six months to two years from now?", asked Jolly. "The market cap is not reflecting the full potential of Enzolytics," said Dr. Chandra, noting the significant market for each of the Company's products. "The next product that we have is ITV-1, which is an HIV therapeutic and has actually cleared Phase III clinical trials and is preparing for introduction into two markets," he explained. "The African market is a significant market because 65% of about 34 to 37 million HIV infected individuals live in Africa."
"We will also be introducing this product into Europe, and are currently awaiting certification under the European Medical Agency," shared Dr. Chandra.
"The global monoclonal antibody market is significant; we are looking at a $144 billion market," continued Dr. Chandra. "We have four monoclonal antibodies for infectious diseases that are in clinical development as we speak."
"As you can imagine, although the market is not reflecting the actual market cap of the company, in the next six months to one year we anticipate a monumental shift in the position of the company as our clinical products start coming to the market ," said Dr. Chandra.
To close the interview, Dr. Chandra encouraged listeners and shareholders to keep up to date with the Company's updates and current projects as they continue to make significant progress across its multiple therapeutic platforms.
To hear Dr. Chandra's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8084060-enzolytics-inc-discusses-the-significance-and-revenue-potential-of-its-therapeutic-platforms-wi
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
About Enzolytics, Inc.
Enzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.
The Company is also implementing its proprietary technology to produce fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. In addition, its proprietary methodology, covered in its pending U.S./PCT Patent Application for producing fully human monoclonal antibodies, is currently employed to produce monoclonal antibody therapeutics for numerous infectious diseases, including the CoronaVirus (SARS-CoV-2) and HTLV-1.
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of its therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
I.R. contact:
Enzolytics Inc.
Company Contact:
Enzolytics, Inc.
Texas A&M Institute for Preclinical Studies
Enzolytics, Inc.
800 Raymond Stotzer Parkway
College Station, Texas 77843-4478
Why is it illegal?
you said:
If you want to find something illegal look at the ENZC press release about SAGA acquiring 2 empty subsidiaries for $250M - now that is illegal.
The subsidiaries are not empty.
What's up with ENZC?
1. The Price
2. Africa ITV-1 treatment
3. Samsung Biologics Website: https://samsungbiologics.com/en
4. Scendea USA, Inc. (www.scendea.com)
5. IPF Immune(TM)
6. SPAC deal with SAGA
7. Abveris, a division of Twist Bioscience Corporation https://www.abveris.com/
8. Effectiveness of ITV-1 immunotherapy on Diabetes.
9. Dividend
10. Development of Feline Leukemia Monoclonal Antibodies
11. Clone 3
12. Production Monoclonal Antibodies against HIV
13. Development Monoclonal Antibodies against the Corona Virus
14. Patents
15. AI
16. Advancing multiple therapeutics targeting numerous infectious diseases
17. Much more yet to be revealed
They went to OTC reporting.
They didn't go dark and they didn't deregister their stock.
Form 15 can be used to deregister their stock or a notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the 1934 Securities Exchange Act.
ENZC (formerly Structural Enhancement Tech Corp) CLEARLY states the filed the form to began reporting under the OTC ALTERNATIVE STANDARDS.
Where is your PROOF that they went dark and deregister their stock?
Timely, Interesting and ACCURATE
ENZC is no longer SEC reporting.
ENZC didn't go "DARK" they went to the OTC.
Timely, Interesting and ACCURATE
Charles is in charge!!!
Tell them what you are going to do.
Do it
Tell what you done.
There will be more unbelievable BLOCKBUSTER news to come.
Probably something in the Monoclonal Antibodies area as they have been working with different companies to get the product to the marketplace.
While it is a long process the foundation is set with Samsung and Abveris, a division of Twist Bioscience Corporation as partners.
COLLEGE STATION, TX / ACCESSWIRE / December 19, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).
Enzolytics, Inc. announces the completion of the 12/31/2020 and 12/31/2021 audited financials. The Company has refiled the 12/31/2021 Disclosure Statement reflecting the completion of the audit covering 2020 and 2021. These filings provide investors with detailed audited information about the Company's operations, business strategies, and financials. The reports will assist the Company's investors in understanding the Company's operations and its focus. In conjunction with the completion of the audits, and as part of the Company's ongoing commitment to transparency and accountability, Enzolytics is planning to become a fully reporting 34 Act Filer with the SEC.
The Company CEO, Charles Cotropia, said, "Enzolytics is focused on accelerating the growth of our clinical products, technology platforms, and multiple applications now in progress. The Company is making substantial advancement in its three synergistic therapeutic platforms generating multiple clinical products for human and veterinary use. Over the last two years, we have focused on advancing our research and development and strengthening our Intellectual Property portfolio covering our technologies. As a result, we have made significant strides and substantive progress on multiple fronts. Our completion of a two-year audit is just one of the many objectives we have set and achieved.
"In the year ahead, Enzolytics will share additional plans regarding our technologies, planned partnerships, and projects, as well as achievements in each of our therapeutics platforms. We have full faith in our long-term vision and mission and are confident in our team's ability to achieve set goals."
The Company's IPF Immune™ therapeutic, a dietary supplement that supports the body's self-defense system, is now available to the public through Onelavi (www.onelavi.com) and through the Company's IPF Immune website (www.enzolyticstherapeutics.com). The product will be widely available through national retailers and their internet platforms and websites. In the coming weeks, the product will be available through Walmart and later through other national outlets. Pre-sales promotions have been aired during the past months, and future promotions and advertising are planned. Product promotion will also be achieved through platforms provided by retailers carrying the product.
To meet demand, additional production of IPF Immune is ongoing. In addition, the Company plans to introduce the product in foreign markets.
The Company COO, Dr. Gaurav Chandra, noted, "At Enzolytics, innovation is driven through our ecosystems with a collective mission to accelerate innovation. Our A.I. platform drives the Company's drug discovery and development and represents an overall strategy to produce therapeutics covered by an all-encompassing Intellectual Property portfolio. We take pride in strengthening our I.P. portfolio covering the anti-virus therapeutics, their method of production, diagnostics and prognostics. Our application of Artificial Intelligent to drug formulation and creation has made possible our move beyond big pharma's monoclonal antibody discovery and development. Enzolytics continues to forge ahead with the immediate strategy to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostic tests, and expand the Company's Patent portfolio.
"In addition, Enzolytics' long-term plan is to be a serious contender in the personalized medicine market. The Company acknowledges the importance of an all-encompassing One Health approach recognizing the link between the health of people, animals, and the environment. As part of that approach, we identified conserved sites for Monkey Pox (https://www.nasdaq.com/press-release/enzolytics-announces-the-discovery-of-conserved-target-sites-on-the-monkeypox-virus) 2 weeks before WHO declared it a Global Public Health Emergency. Enzolytics continues to partner and engage with technology, genetics, veterinary centers, diagnostic and regulatory companies applying that strategy in each of these areas."
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or any comparable regulatory agencies elsewhere in the world.
While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Enzolytics to establish the efficacy of its therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove accurate.
Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.
Company Contact:
Enzolytics, Inc.
Texas A&M University Institute for Preclinical Studies
College Station, TX 77843-44
www.enzolytics.com
SOURCE: Enzolytics, Inc.
Oldies but Goodies are rolling through here.
It is going to to get CRAZY with ENZC and SAGA in the upcoming days, weeks and months.
Finding out the details of the SAGA deal
Closing the deal
Africa update
IPF Immune sales
Dividend
The bottom line for ENZC is the world will sooner than later find out just how DISRUPTIVE its' technology is!!!
Yep,
It is a very cloudy situation that will become clearer once more information is released.
How did ENZC get to where they are today?
Hard work in the laboratory
What did they share with SAGA that they will pay ENZC 250 Million dollars?
Don't know however it must have been a hell of a sale
Who are these pipe investors bringing up the rear?
Don't know
Are we getting shares of SAGA Scientific Holdings Corp.?
This is an interesting question because under a "normal" SPAC a private/public (the target) company gets bought out/merged with the SPAC and shares are distributed with the target getting the majority shares.
In our situation we are selling two subsidiaries for $250,000,000 while the Parent company remains intact.
This creates uncertainty as to if we get shares.
IMO I think we get some because for one our management team is running the new company (which is normal under SPAC) and some of our technology that wasn't part of the original license agreements is being used in the new company.
Formation of Two New Wholly-Owned Subsidiaries
Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDINGPEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
What will the dividend be?
Don't know
When will we get an Africa ITV-1 therapeutic update?
Soon I hope
Enzolytics is a time bomb with a LIT fuse with many warheads attached going in different directions that is about to BLOW time after time.
Watch out!!!
Didn't
https://investor.regeneron.com/static-files/dbe7aad3-8aff-483f-9366-fa1678d7b738
Multiple potential FDA submissions: 2023-2025+
DUPIXENT*
Type 2 COPD
LIBTAYO
Adjuvant CSCC
Fianlimab + LIBTAYO
Advanced Melanoma
PRALUENT
Pediatric HeFH (mid)
DUPIXENT*
CPUO
Pozelimab ± cemdisiran+
C5-mediated diseases
Odronextamab
B-Cell NHL (2H)
DUPIXENT*
Bullous Pemphigoid
Garetosmab
FOP
Linvoseltamab
R/R Multiple Myeloma (2H)
Aflibercept 8 mg
RVO
Itepekimab*
COPD
M
Actually not.
With most SPAC deals different entities getting certain percentages of the newly formed company.
This isn't your run of the mill SPAC deal so it is really hard to speculate as what will occur.
List of Companies That Went Public By Merging With A Special Purpose Acquisition Company ('SPAC')
https://stockmarketmba.com/listofcompaniesthathavemergedwithaspac.php
I look at a lot of companies that went the SPAC route and found mixed results.
Most SPAC trade around $10 and soon after the deal closes a lot of them drop significantly. Some recovered some didn't.
MoonLake Immunotherapeutics (MLTX) completed SPAC on 4/5/2022 and closed at $13.25.
Closed on 5/5/2022 at $5.73
Closed on 11/5/2002 at $8.49
Closed on 4/21/2023 at $21.67
EQRx, Inc. (EQRX) completed SPAC on 12/17/2021and closed at $8.29
Closed on 1/18/2022 at $6.28
Closed on 7/18/2022 at $5.00
Closed on 12/16/2022 at $2.18
Closed on 4/21/2023 at $1.85
The bottom line is the SPAC gets you to a higher exchange or to become a public trading company however companies must perform, must produce, must provide results.
ENZC was already performing, producing and is on the verge of providing significant results with the deployment of ITV-1 therapeutic to Africa.
There are many unanswered questions as to how and what will be distributed.
Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ: SAGA) ("Sagaliam"), a special purpose acquisition company ("SPAC"), announced today, April 17, 2023, they have executed a non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics, Inc. ("VIRO"), operating subsidiaries of Enzolytics. The value of the transaction is $250,000,000 The definitive agreement is being finalized with an expected closing date of May 19, 2023.
So $250,000,000 is the value of the transaction.
Sagaliam Acquisition Corp Market capitalization is $157.53 million so they are around $100 million short of the $250 million.
A lot of the deals I look at were broken out by different entities getting certain percentages of the newly formed company.
It is possible we get a percentage to cover the $100 million.
The transaction, once completed, will provide BGEN and VIRO with significant additional capital to continue their development and expansion of existing and future technology platforms. In addition, Sagaliam expects to raise additional capital through a private investment in public equities ("PIPE"). The anticipated capital raise from the PIPE is expected to be primarily used by BGEN and VIRO to pay transaction-related expenses and fund the clinical trials of ITV-1, marketing of IPF Immune™, production of fully human monoclonal antibodies (mAbs) and continued advancement in its proprietary technology involving the application of Artificial Intelligence (AI) in therapeutic discoveries and production.
The mAbs and AI wasn't in the original patent license agreements for BGEN and VIRO. Heck AI wasn't even on the radar.
They are there now as they are specifically noted.
Now for the dividend.
ENZC would like to provide additional information and clarification regarding the recent announcement of the sale of Biogenysis ("BGEN") and Virogentics ("VIRO") to Sagaliam Acquisition Corp. (NASDAQ: SAGA) ("Sagaliam"), a special purpose acquisition company ("SPAC"). After any required approval of the transaction by the various regulatory authorities, the Company intends to issue a dividend of the sales proceeds to ENZC shareholders on the date of record of the declared and approved dividend. ENZC shares will continue to trade on the OTC PINK Market. The sale transaction will not interfere with the trading of ENZC stock. Regarding the definitive purchase agreement, it is being finalized with an expected execution date of May 19, 2023. The previous release stated the transaction was expected to close on May 19, 2023, which was an error. Once the transaction document is finalized it will be subject to regulatory approval.
What will the dividend be?
Cash, stock or a little of both.
Dividend refers to a reward, cash or otherwise, that a company gives to its shareholders. Dividends can be issued in various forms, such as cash payment, stocks or any other form. A company's dividend is decided by its board of directors and it requires the shareholders' approval.
Cash is straight forward.
I suspect or should I say expect ENZC will be giving shares of the newly form company to make up for the $100 million shortfall and those shares should be passed on to the shareholders.
Interesting, Timely, Accurate
Dividends are not based on how long one holds a stock.
Companies pay dividends because the have the means to do so.
ENZC will have 250 million at their disposal and has decided to share it with their shareholders via a dividend.
We won't know the ex-date or record date until ENZC have the money/stocks in their account(s).
What Is a Dividend?
A dividend is the distribution of a company's earnings to its shareholders and is determined by the company's board of directors.
Announcement date: Dividends are announced by company management on the announcement date (or declaration date) and must be approved by the shareholders before they can be paid.
Ex-dividend date: The date on which the dividend eligibility expires is called the ex-dividend date or simply the ex-date. For instance, if a stock has an ex-date of Monday, May 5, then shareholders who buy the stock on or after that day will NOT qualify to receive the dividend. Shareholders who own the stock one business day prior to the ex-date, on Friday, May 2, or earlier, qualify for the distribution.
Record date: The record date is the cutoff date, established by the company to determine which shareholders are eligible to receive a dividend or distribution.
Payment date: The company issues the payment of the dividend on the payment date, which is when the money gets credited to investors' accounts.
Also they didn't the mention the next gen covid on slide 25:
No,
Companies pay dividends because the have the means to do so and it is not a bad strategy to keep shareholders as some companies pay dividends regularly.
It has nothing to do with rewarding those who hold.
The company hasn't even disclosed a record date or ex-date.
No
IMHO maximin 100 ENZC to 1 SAGA Scientific Holdings Corp
Minimum 1000 ENZC to 1 SAGA Scientific Holdings Corp
I also think this will be part of the final binding agreement and has nothing to do with ENZC paying a dividend from the $250 million.
Remember we own BGEN and VIRO and we should get a piece of the new company.
Ran hard to .1011
Compressed down to .07595
Preparing for next leg up
Definite flipping as expected and will continue throughout the upcoming days, weeks and months.
What will the next PR reveal?
When will it be released?
Major rally days are in the forecast.
More bigger and powerful than the all encompassing OTC February 2021 run.
ENZC was just teething back then.
Now they have permanent teeth.
Many more eyes on it with all the speculation, possibilities and probabilities at stake.
Gonna be a heck of a ride.
What is going on with ENZC?
Well they have somebody interested in their technology.
There is a proposal on the table and people are rolling the dice to get a piece of the pie.
There are people getting In who were around from February 2021 run there are new people who heard about the run and there are people who just heard about ENZC.
One thing to consider is how much we were buying in the early days up to during and after the first run.
That may probably will could should happen however I expect to be bigger and greater than when we were involved.
The thing is that ENZC has moved exponentially in the laboratory since the last run.
The are multiple factors that can put pressure on the stock movement.
Africa
Agreement closing
Clearer dividend distribution
Whatever else ENZC haven't shared with us yet.
AIMHO
When ENZC was selling for that price it was overinflated with the rest of the OTC in February 2021. I had OTC stocks that rose like crazy for no reason at all. ENZC was no different.
ENZC stayed overinflated for months after the big run up with all the hype around the technology that the company possessed.
It took a long time for ENZC to bring a product to the marketplace.
Now with IPF Immune in the marketplace, ITV-1 being deployed to Africa and the non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics, Inc. we have a legitimate reason to see some upward movement of the stock price.
How much volume and how high the stock price will rise is certainly unknown however with all the recent news and the future plans it going to be very very interesting.
AIMHO
ENZC and us shareholders are about to entered uncharted territory.
Normally with a SPAC a company get bought out by SPAC and become new entity and move on from there.
ENZC is selling two operating subsidiaries which they will be handsomely paid and get a percentage of the newly formed entity.
I expect ENZC shareholders to get shares of SAGA Scientific Holdings Corp.
Will ENZC the company get shares of SAGA Scientific Holdings Corp. to go into its treasury?
Why is this uncharted territory for ENZC?
All the current programs ENZC have been working on are going to be flip into SAGA Scientific Holdings Corp along with personnel.
ITV-1, marketing of IPF Immune™, production of fully human monoclonal antibodies (mAbs) and continued advancement in its proprietary technology involving the application of Artificial Intelligence (AI) in therapeutic discoveries and production.
BGEN will continue to operate under the direction of Dr. Gaurav Chandra as Chairman and CEO and Charles Cotropia as BGEN Director.
VIRO will continue to be managed by Diana Zhabilov as Chairman and CEO and Harry Zhabilov as its CSO and Director, furthering the progress on clinical trials and permitting through the EMA of ITV-1, marketing of IPF Immune™ in the United States as well as registration in Europe, development of the multiple sclerosis treatment and a new initiative involving the use of ITV-1 to treat diabetes. Dr. Lachezar Ivanov will continue to provide invaluable consulting services to VIRO.
Right now the most important technology for ENZC is the ITV-1 therapeutic as it is being deployed to Africa to be administered over a 17 week period once the treatments starts. This will be an international news event at some point during and after the treatment period. What we know about the previous clinical trials for ITV-1 there probably will be good if not great results.
We have limited information on how the SPAC deal will be broken down.
Here is what is being dealt:
SAGA gets Biogenysis, Inc. and Virogentics, Inc. for $250,000,000.
Formation of Two New Wholly-Owned Subsidiaries
Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc.
Two Patent License Agreements
On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDINGPEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof.
Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof.
https://www.otcmarkets.com/otcapi/company/financial-report/265788/content
What we don't know is the share count for BGEN and VIRO.
We the shareholders own BGEN and VIRO so we will be getting a piece of the pie.
Basically with SPAC deals, the shares from the company being bought out flips over to the new company.
Based on the information released up-to-date IMHO I believe ENZC gets a piece of the new company which is normal with SPACs.
Also what is normal with SPACs is the company's management being bought out usually run the newly formed entity.
How that translate to ENZC individual shareholders is a wait and see.
Press Release Highlights:
The Extension is the fifth of ten one-month extensions permitted under Sagaliam's governing documents and provides the Company with additional time to complete its business combination.
Now, after almost two and a half years, with planned clinical trials and studies, the Company sees this as the right time to align the talents in the Company to focus on successful advancement of the distinctive technologies within Enzolytics.
Our AI platform and the collaboration we have with Samsung Biologics will accelerate our progress. Since the steps from early discovery to IND studies are identical, we can move ahead rapidly with production of multiple Monoclonal Antibodies."
The Company plans to create an Artificial Intelligence division to develop drug discovery and development strategies. Dr. Bischof said, "Large pharmaceutical companies are creating internal algorithms and partnering with or acquiring new companies to use AI to increase their portfolios and pipelines. With an increased focus on AI-empowered Drug Discovery Platforms that allow the discovery of multiple drugs with multiple targets and applications, we continue to consider collaborations with our AI platform.
In addition, we are creating a strong IP portfolio for multiple infectious diseases covering diagnostics, therapeutics, and vaccines for these viruses. Strategically, we are focused on meeting milestones and licensing each of these assets. The SPAC agreement allows us to move forward with multiple Monoclonal Antibodies simultaneously, bringing significant value to our shareholders."
It is quite plausible that ENZC gets a percentage of the new company as they will be running it.
Also SAGA isn't sitting on $250 million.
List of Companies That Went Public By Merging With A Special Purpose Acquisition Company ('SPAC')
https://stockmarketmba.com/listofcompaniesthathavemergedwithaspac.php
I look at a lot of companies that went the SPAC route and found mixed results.
Most SPAC trade around $10 and soon after the deal closes a lot of them drop significantly. Some recovered some didn't.
MoonLake Immunotherapeutics (MLTX) completed SPAC on 4/5/2022 and closed at $13.25.
Closed on 5/5/2022 at $5.73
Closed on 11/5/2002 at $8.49
Closed on 4/21/2023 at $21.67
EQRx, Inc. (EQRX) completed SPAC on 12/17/2021and closed at $8.29
Closed on 1/18/2022 at $6.28
Closed on 7/18/2022 at $5.00
Closed on 12/16/2022 at $2.18
Closed on 4/21/2023 at $1.85
The bottom line is the SPAC gets you to a higher exchange or to become a public trading company however companies must perform, must produce, must provide results.
ENZC was already performing, producing and is on the verge of providing significant results with the deployment of ITV-1 therapeutic to Africa.
There are many unanswered questions as to how and what will be distributed.
Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ: SAGA) ("Sagaliam"), a special purpose acquisition company ("SPAC"), announced today, April 17, 2023, they have executed a non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics, Inc. ("VIRO"), operating subsidiaries of Enzolytics. The value of the transaction is $250,000,000 The definitive agreement is being finalized with an expected closing date of May 19, 2023.
So $250,000,000 is the value of the transaction.
Sagaliam Acquisition Corp Market capitalization is $157.53 million so they are around $100 million short of the $250 million.
A lot of the deals I look at were broken out by different entities getting certain percentages of the newly formed company.
It is plausible we get a percentage to cover the $100 million.
The newly formed company stock from SPAC deals will rise or fall based on the company results.
SAGA Scientific Holdings Corp. will probably fall soon after trading however with the ITV-1 results from the African rollout expected near the end of Summer (August) with possible updates in between, it could start an epic rise.
List of Companies That Went Public By Merging With A Special Purpose Acquisition Company ('SPAC')
https://stockmarketmba.com/listofcompaniesthathavemergedwithaspac.php
I look at a lot of companies that went the SPAC route and found mixed results.
Most SPAC trade around $10 and soon after the deal closes a lot of them drop significantly. Some recovered some didn't.
MoonLake Immunotherapeutics (MLTX) completed SPAC on 4/5/2022 and closed at $13.25.
Closed on 5/5/2022 at $5.73
Closed on 11/5/2002 at $8.49
Closed on 4/21/2023 at $21.67
EQRx, Inc. (EQRX) completed SPAC on 12/17/2021and closed at $8.29
Closed on 1/18/2022 at $6.28
Closed on 7/18/2022 at $5.00
Closed on 12/16/2022 at $2.18
Closed on 4/21/2023 at $1.85
The bottom line is the SPAC gets you to a higher exchange or to become a public trading company however companies must perform, must produce, must provide results.
ENZC was already performing, producing and is on the verge of providing significant results with the deployment of ITV-1 therapeutic to Africa.
There are many unanswered questions as to how and what will be distributed.
Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ: SAGA) ("Sagaliam"), a special purpose acquisition company ("SPAC"), announced today, April 17, 2023, they have executed a non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics, Inc. ("VIRO"), operating subsidiaries of Enzolytics. The value of the transaction is $250,000,000 The definitive agreement is being finalized with an expected closing date of May 19, 2023.
So $250,000,000 is the value of the transaction.
Sagaliam Acquisition Corp Market capitalization is $157.53 million so they are around $100 million short of the $250 million.
A lot of the deals I look at were broken out by different entities getting certain percentages of the newly formed company.
It is possible we get a percentage to cover the $100 million.
The transaction, once completed, will provide BGEN and VIRO with significant additional capital to continue their development and expansion of existing and future technology platforms. In addition, Sagaliam expects to raise additional capital through a private investment in public equities ("PIPE"). The anticipated capital raise from the PIPE is expected to be primarily used by BGEN and VIRO to pay transaction-related expenses and fund the clinical trials of ITV-1, marketing of IPF Immune™, production of fully human monoclonal antibodies (mAbs) and continued advancement in its proprietary technology involving the application of Artificial Intelligence (AI) in therapeutic discoveries and production.
The mAbs and AI wasn't in the original patent license agreements for BGEN and VIRO. Heck AI wasn't even on the radar.
They are there now as they are specifically noted.
Now for the dividend.
ENZC would like to provide additional information and clarification regarding the recent announcement of the sale of Biogenysis ("BGEN") and Virogentics ("VIRO") to Sagaliam Acquisition Corp. (NASDAQ: SAGA) ("Sagaliam"), a special purpose acquisition company ("SPAC"). After any required approval of the transaction by the various regulatory authorities, the Company intends to issue a dividend of the sales proceeds to ENZC shareholders on the date of record of the declared and approved dividend. ENZC shares will continue to trade on the OTC PINK Market. The sale transaction will not interfere with the trading of ENZC stock. Regarding the definitive purchase agreement, it is being finalized with an expected execution date of May 19, 2023. The previous release stated the transaction was expected to close on May 19, 2023, which was an error. Once the transaction document is finalized it will be subject to regulatory approval.
What will the dividend be?
Cash, stock or a little of both.
Dividend refers to a reward, cash or otherwise, that a company gives to its shareholders. Dividends can be issued in various forms, such as cash payment, stocks or any other form. A company's dividend is decided by its board of directors and it requires the shareholders' approval.
Cash is straight forward.
I suspect or should I say expect ENZC will be giving shares of the newly form company to make up for the $100 million shortfall and those shares should be passed on to the shareholders.
Interesting, Timely, Accurate